277 related articles for article (PubMed ID: 19195860)
1. PKC inhibitors: potential in T cell-dependent immune diseases.
Baier G; Wagner J
Curr Opin Cell Biol; 2009 Apr; 21(2):262-7. PubMed ID: 19195860
[TBL] [Abstract][Full Text] [Related]
2. PKCtheta: A potential therapeutic target for T-cell-mediated diseases.
Chaudhary D; Kasaian M
Curr Opin Investig Drugs; 2006 May; 7(5):432-7. PubMed ID: 16729719
[TBL] [Abstract][Full Text] [Related]
3. Selective modulation of protein kinase C-theta during T-cell activation.
Monks CR; Kupfer H; Tamir I; Barlow A; Kupfer A
Nature; 1997 Jan; 385(6611):83-6. PubMed ID: 8985252
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological regulation of network kinetics by protein kinase C localization.
Mochly-Rosen D; Kauvar LM
Semin Immunol; 2000 Feb; 12(1):55-61. PubMed ID: 10723798
[TBL] [Abstract][Full Text] [Related]
5. The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation.
Evenou JP; Wagner J; Zenke G; Brinkmann V; Wagner K; Kovarik J; Welzenbach KA; Weitz-Schmidt G; Guntermann C; Towbin H; Cottens S; Kaminski S; Letschka T; Lutz-Nicoladoni C; Gruber T; Hermann-Kleiter N; Thuille N; Baier G
J Pharmacol Exp Ther; 2009 Sep; 330(3):792-801. PubMed ID: 19491325
[TBL] [Abstract][Full Text] [Related]
6. Selective function of PKC-theta in T cells.
Manicassamy S; Gupta S; Sun Z
Cell Mol Immunol; 2006 Aug; 3(4):263-70. PubMed ID: 16978534
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and clinical development of novel agents that target the protein kinase C family.
Serova M; Ghoul A; Benhadji KA; Cvitkovic E; Faivre S; Calvo F; Lokiec F; Raymond E
Semin Oncol; 2006 Aug; 33(4):466-78. PubMed ID: 16890801
[TBL] [Abstract][Full Text] [Related]
8. Effect of fever-like whole-body hyperthermia on lymphocyte spectrin distribution, protein kinase C activity, and uropod formation.
Wang XY; Ostberg JR; Repasky EA
J Immunol; 1999 Mar; 162(6):3378-87. PubMed ID: 10092792
[TBL] [Abstract][Full Text] [Related]
9. Emerging and diverse roles of protein kinase C in immune cell signalling.
Tan SL; Parker PJ
Biochem J; 2003 Dec; 376(Pt 3):545-52. PubMed ID: 14570590
[TBL] [Abstract][Full Text] [Related]
10. Stromal cell-derived factor 1-alpha (SDF)-induced human T cell chemotaxis becomes phosphoinositide 3-kinase (PI3K)-independent: role of PKC-theta.
Shahabi NA; McAllen K; Sharp BM
J Leukoc Biol; 2008 Mar; 83(3):663-71. PubMed ID: 18055570
[TBL] [Abstract][Full Text] [Related]
11. T-cell fate and function: PKC-theta and beyond.
Marsland BJ; Kopf M
Trends Immunol; 2008 Apr; 29(4):179-85. PubMed ID: 18328786
[TBL] [Abstract][Full Text] [Related]
12. PKD at the crossroads of DAG and PKC signaling.
Wang QJ
Trends Pharmacol Sci; 2006 Jun; 27(6):317-23. PubMed ID: 16678913
[TBL] [Abstract][Full Text] [Related]
13. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
van der Merwe JQ; Moreau F; MacNaughton WK
Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase C beta inhibitors: a new therapeutic target for diabetic nephropathy and vascular complications.
Budhiraja S; Singh J
Fundam Clin Pharmacol; 2008 Jun; 22(3):231-40. PubMed ID: 18485142
[TBL] [Abstract][Full Text] [Related]
15. Structure-based optimization of PKCtheta inhibitors.
Mosyak L; Xu Z; Joseph-McCarthy D; Brooijmans N; Somers W; Chaudhary D
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1027-31. PubMed ID: 17956269
[TBL] [Abstract][Full Text] [Related]
16. Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors.
Cole DC; Asselin M; Brennan A; Czerwinski R; Ellingboe JW; Fitz L; Greco R; Huang X; Joseph-McCarthy D; Kelly MF; Kirisits M; Lee J; Li Y; Morgan P; Stock JR; Tsao DH; Wissner A; Yang X; Chaudhary D
J Med Chem; 2008 Oct; 51(19):5958-63. PubMed ID: 18783200
[TBL] [Abstract][Full Text] [Related]
17. Competitive inhibitors and allosteric activators of protein kinase C isoenzymes: a personal account and progress report on transferring academic discoveries to the clinic.
Budas GR; Koyanagi T; Churchill EN; Mochly-Rosen D
Biochem Soc Trans; 2007 Nov; 35(Pt 5):1021-6. PubMed ID: 17956268
[TBL] [Abstract][Full Text] [Related]
18. 2,6-Naphthyridines as potent and selective inhibitors of the novel protein kinase C isozymes.
van Eis MJ; Evenou JP; Floersheim P; Gaul C; Cowan-Jacob SW; Monovich L; Rummel G; Schuler W; Stark W; Strauss A; von Matt A; Vangrevelinghe E; Wagner J; Soldermann N
Bioorg Med Chem Lett; 2011 Dec; 21(24):7367-72. PubMed ID: 22078216
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase C intervention: the state of play.
Roffey J; Rosse C; Linch M; Hibbert A; McDonald NQ; Parker PJ
Curr Opin Cell Biol; 2009 Apr; 21(2):268-79. PubMed ID: 19233632
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C-theta inhibitors: a novel therapy for inflammatory disorders.
Chand S; Mehta N; Bahia MS; Dixit A; Silakari O
Curr Pharm Des; 2012; 18(30):4725-46. PubMed ID: 22830352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
